TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant



Status:Recruiting
Conditions:Post-Surgical Pain, Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Musculoskeletal, Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:11/11/2018
Start Date:October 4, 2018
End Date:April 1, 2020
Contact:Ana Arias, BS
Email:apaarias@ucdavis.edu
Phone:916-703-5456

Use our guide to learn which trials are right for you!

Transversus Abdominis Plane (TAP) Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine: A Prospective Randomized Control Trial for Pain Control After Renal Transplant Surgery

This study is a comparison of the analgesic efficacy of transversus abdominis plane (TAP)
blocks with ropivacaine bolus plus continuous ropivacaine infusion via catheters versus
single shot TAP blocks with liposomal bupivacaine.

This study is a comparison of the analgesic efficacy of TAP blocks provided by ropivacaine
bolus plus continuous ropivacaine infusion via catheters versus single shot TAP blocks with
liposomal bupivacaine.

In the Liposomal Bupivacaine group, TAP block will be performed using ultrasound guidance.
12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP.
Liposomal Bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of
preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected
into the TAP.

For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP
block and 5 mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter
will be placed approximately 3-5 cm into the TAP space after injection of ropivacaine. A
bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a
maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8
ml/hr of 0.2% ropivacaine on the inpatient floor.

Inclusion Criteria:

- Patients ages 18 years or older

- Renal Transplant Recipients

Exclusion Criteria:

- Patients less than 18 years of age

- Pregnant Women

- Prisoners

- Opioid Tolerant Patients taking more than 30 mg/day of oral morphine equivalent
analgesia

- Patients on Systemic anti coagulation

- Patients unable to provide consent

- Hypersensitivity to amide-type local anesthetic or any component of the drug formula
We found this trial at
1
site
1 Shields Ave
Sacramento, California 95616
(530) 752-1011
Principal Investigator: Richard Applegate, MD
Phone: 916-703-5456
University of California-Davis As we begin our second century, UC Davis is poised to become...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials